News
FIRDAPSE boosts Catalyst's strong Q1 2025 results, beating forecasts. With 15–20% growth projected, see why analysts rate ...
Intellia’s stock fell 23% after one patient in its Phase III MAGNITUDE trial developed severe liver toxicity that later ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback